Diagnostic accuracy of rapid point-of-care tests for diagnosis of current SARS-CoV-2 infections in children: A systematic review and meta-analysis

Naomi Fujita-Rohwerder, PhD [*1,2], Lars Beckmann, Dr [2], Yvonne Zens, MPH [2], Arpana Verma, PhD [1]

[1]Faculty of Biology, Medicine and Health, University of Manchester, Manchester, United Kingdom; [2]Institute for Quality and Efficiency in Health Care (IQWiG), Cologne, Germany

***Corresponding Author:**

Dr. Naomi Fujita-Rohwerder
Institute for Quality and Efficiency in Health Care (IQWiG)
Im Mediapark 8
50670 Cologne
Germany

E-Mail: naomi.fujita-rohwerder@iqwig.de

Sources of financial assistance: None.

Potential conflicts of interest: The authors declare no conflicts of interest.

Keywords: rapid test, antigen test, molecular test, children, pediatric, SARS-CoV-2, COVID-19, diagnostic accuracy, sensitivity, specificity, systematic review, meta-analysis

ABSTRACT

Objective: To systematically assess the diagnostic accuracy of rapid point-of-care tests for diagnosis of current SARS-CoV-2 infections in children under real-life conditions.

Study design: Multiple bibliographic databases including MEDLINE and Embase, clinical trial registries and further information sources were systematically searched for literature (last bibliographic search: May 7, 2021). Diagnostic cross-sectional or cohort studies that included pediatric study participants and evaluated rapid point-of care tests for diagnosing current SARS-CoV-2 infections against RT-PCR as the reference standard were eligible for inclusion. QUADAS-2 was used to assess the risk of bias and the applicability of the included studies. Bivariate meta-analyses with random effects were performed. Variability was assessed by subgroup analyses.

Results: We included 17 studies with a total of 6355 pediatric study participants. All included studies compared antigen tests against RT-PCR. Only one study was at low risk of bias. The pooled overall diagnostic sensitivity and specificity in pediatric populations was 64.2% (95% CI: 57.4%-70.5%) and 99.1% (95% CI: 98.2%-99.5%), respectively. In symptomatic children, the pooled diagnostic sensitivity was 71.8% (95% CI: 63.6%-78.8%) and the pooled diagnostic specificity was 98.7% (95% CI: 96.6%-99.5%). The pooled diagnostic sensitivity in asymptomatic children was 56.2% (95% CI: 47.6%-64.4%) and the pooled diagnostic specificity was 98.6% (95% CI: 97.3%-99.3%).

Conclusions: Performance of current antigen tests under real-life conditions varies broadly. Policymakers should especially be aware of the low diagnostic sensitivity of current antigen tests. Results should be interpreted with caution since risk of bias was predominantly judged as unclear due to poor reporting.

Study registration: CRD42021236313 (PROSPERO).

INTRODUCTION

Since the beginning of the coronavirus disease 19 (COVID-19) pandemic caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in spring 2020, an accurate, fast, and early detection of individuals infected with SARS-CoV-2 followed by effective isolation measures of infected individuals has been considered a cornerstone in the global fight against the spread of SARS-CoV-2. Laboratory-based reverse transcription-polymerase chain reaction (RT-PCR) testing is the standard for diagnosing current infections with SARS-CoV-2. However, limited testing capacities at many laboratories worldwide and limited availability of laboratories in developing countries demonstrated the urgent need for novel diagnostic tests that are easy to use, less expensive, widely available, and suitable for point-of-care use. Today, such tests – and in particular antigen tests – are increasingly used to complement testing with RT-PCR to extend testing capacities or when a short turnaround time is essential [1]. However, the advantages of antigen tests come at the price of lower diagnostic accuracy, most notably a lower diagnostic sensitivity, which increases the risk of missing cases, including pre-symptomatic infected individuals who have yet to enter the most infectious period [2]. Whether a lower sensitivity can be compensated by frequent testing remains controversially discussed [3–6]. Further, the fact that sensitivity and specificity are no inherent test characteristics but are rather affected by various factors, including population characteristics, sample quality, and study design, needs consideration [7]. Data on diagnostic accuracy provided by antigen test manufacturers at market access is often overly optimistic and does not necessarily reflect the test's performance in practice. A recent Cochrane Review [8] showed that the sensitivity of antigen tests in adult populations varies considerably across brands, with only a few tests meeting the minimum acceptable sensitivity of ≥ 80% as defined by the World Health Organization (WHO) or the United States Food and Drug Administration (US FDA) [9,10]. Since many countries are implementing public health safety measures that involve the use of antigen tests not only in adults but also in children, such as mass (self-)testing in schools [11], knowledge about how these tests perform in children is of high importance. However, to our knowledge, no systematic review

has analyzed the diagnostic test accuracy (DTA) of rapid tests in children yet. Therefore, in this systematic review and meta-analysis, we aimed to identify, assess, and summarize the best available evidence on the real-life performance of rapid tests for diagnosing current SARS-CoV-2 infections in pediatric populations at the point of care.

METHODS

The protocol for this systematic review was registered with PROSPERO, the international prospective register of systematic reviews (ID: CRD42021236313) [12]. The reporting of this systematic review adhered to the Preferred Reporting Items for Systematic reviews and Meta-Analyses of DTA studies (PRISMA-DTA) guideline [13] and two relevant extensions "PRISMA-DTA for Abstracts" [14] and "PRISMA-S for Reporting Literatures Searches in Systematic Reviews" [15]. The completed PRISMA checklists are available in **Appendix 1**.

Eligibility Criteria

We included diagnostic cross-sectional and cohort studies that evaluated the clinical performance of rapid point-of-care tests for detecting current SARS-CoV-2 infections against the reference standard in pediatric or mixed-age populations. Assessing analytical performance parameters such as the analytical sensitivity (limit of detection) or the analytical specificity (cross-reactivity) was not subject of the current review. Diagnostic case-control studies were excluded as they reflect the test's performance under ideal conditions and, therefore, often overestimate the diagnostic accuracy [16]. Moreover, studies evaluating serological tests were excluded as such tests are not suitable for the initial diagnosis of current SARS-CoV-2 infection [17]. We considered a study as eligible if the study population comprised at least ten pediatric study participants, each identified as positive or negative by the reference standard. Laboratory-based RT-PCR alone or in combination with clinical findings or clinical follow-up was defined as the reference standard since it reflects the best available method for diagnosing individuals currently infected with SARS-CoV-2 [7]. Further,

we required reporting of data that allowed constructing a complete 2x2 contingency table. The full set of eligibility criteria is shown in **Table 1**. For studies that did not fully meet the inclusion criteria for the population, index test and/or reference standard, we required that at least 80% of the pediatric (sub-)population matched the population we defined for this systematic review. Studies were excluded, if the index test and the reference standard were performed in less than 80% of the pediatric study population. Besides journal articles, reports (including clinical study reports) that adhered to reporting standards such as STARD [18] or recommendations given by government agencies [10,19] were considered eligible for inclusion. Studies that mentioned the inclusion of pediatric study participants without reporting any corresponding outcome data but otherwise met the eligibility criteria were preliminary included, and study authors were contacted and asked to provide such data. Further, if the study population's baseline characteristics included information on age, we estimated the proportion of pediatric study participants assuming ages of study participants following a normal distribution and the proportion of PCR-positive pediatric assuming no changes in the PCR positivity rate among age groups. We contacted authors if we estimated at least 10 PCR-positive pediatric study participants in the study population.

Information Sources

We performed a comprehensive search for primary studies and secondary publications (systematic reviews and Health Technology Assessment (HTA) reports) in the following electronic bibliographic databases: MEDLINE (Ovid), Embase (Ovid), the Cochrane Library (Wiley), and preprint servers (Europe PMC) including medRxiv and bioRxiv (see [20] for full list of included preprint servers). Here, secondary publications were solely used as sources for potentially relevant studies. In addition, we searched two study registries (ClinicalTrials.gov and the WHO International Clinical Trials Registry Platform (ICTRP)) for relevant clinical studies. Other information sources comprised the International HTA Database, the Foundation of Innovative Diagnostics (FIND) COVID-19 website, and the

Evidence Search and Guidance websites of Britain's National Institute for Health and Care Excellence (NICE).

Search Strategy

In accordance with the Cochrane Handbook for DTA Reviews [21], the search strategy included concepts addressing the index test and the target condition. The development of the search strategy followed an objective approach that involved text-analytic procedures to identify candidate search terms based on the method described by Hausner et al. [22]. One researcher performed analyses of simple word frequencies and keywords-in-contexts in R using the Quanteda package [23]. Because of substantial differences between types of tests, separate test sets were used to identify candidate search terms for antigen tests and molecular tests, respectively. Test sets included potentially relevant studies (irrespective of pediatric study participants) from the Cochrane Review by Dinnes et al. [8] and from a frequently updated website that lists DTA studies on antigen tests [24]. Due to a limited number of potentially relevant references addressing rapid molecular tests for point-of-care usage, the draft search strategy was supplemented by search terms derived from a conceptual approach. Furthermore, brand names of tests included in the Cochrane Review were added to increase sensitivity. The final search strategy was tested for completeness against the validation sets and relevant references of studies that included pediatric participants identified via exploratory searches beforehand. Prior to execution, the search strategy was peer-reviewed by a senior information specialist following the Peer Review of Electronic Search Strategies (PRESS) Guideline statement [25].

We only searched for publications published after December 2019, as we were only interested in literature published after the emergence of SARS-CoV-2. Further, we limited our search to publications written in English or German. Since Embase and MEDLINE provided comprehensive search filters for SARS-CoV-2 related literature via Ovid, our concept addressing the target condition was not used in these two searches.

To acknowledge the unprecedented role of preprints in the rapid dissemination of SARS-CoV-2 related research, we also searched for relevant preprints. Due to the direct availability of full texts of preprints and to increase the efficiency of the information retrieval, a further concept addressing the target population was defined and used in addition to the standard search strategy for identifying potentially relevant preprints directly at the full-text level. We assumed that this approach allowed to increase the precision of the overall search without a relevant reduction of its comprehensiveness.

All search strategies are provided in **Appendix 2**. The last search in bibliographic databases and study registries was conducted on May 7, 2021. Other information sources were last searched on May 24, 2021. Endnote X9.3 was used for citation management. Due to the more specific separate search for preprints at full-text level, any preprint records identified from MEDLINE were removed. Duplicates were initially eliminated via Ovid's deduplication feature. After exporting all identified references from Ovid, duplicates were identified in R by comparing DOIs of references from MEDLINE and Embase, and the Embase records of duplicates were removed. Remaining duplicates were manually removed in EndNote X9.3 and by using Endnote's "find duplicates" function. Further, records from ClinicalTrials.gov that were retrieved from the WHO's ICTRP website were removed since directly accessing ClinicalTrials.gov's registry data allows for a more comprehensive search for relevant studies.

Study Selection

The screening of literature retrieved from bibliographical databases involved a 2-step screening procedure and was performed independently by two researchers using the web-based Trial Selection Database (webTSDB) [26]. In a first step, potentially eligible primary studies and secondary publications were identified from screening titles and abstracts of retrieved citations. In a second step, the full texts of these articles were obtained and evaluated. Publications that met the eligibility criteria were included. Any discrepancies were resolved by consensus between the two researchers before finalizing each screening step.

Reference lists of relevant systematic reviews and HTAs (independent of mentioning pediatric study participants) were manually screened to identify further relevant studies. For the screening of records from study registries, both screening steps were combined. Furthermore, documents identified through searching other information sources were screened for eligibility or information about potentially relevant studies.

Data Collection

The individual steps of data collection were performed by one researcher. All output was checked by a second researcher to ensure its validity and completeness. Any disagreements were resolved by consensus. At first, a standardized Excel spreadsheet was developed for data extraction. The spreadsheet was piloted before data extraction commenced. Extracted data included information on the general study characteristics, study participant characteristics, index test, reference standard, flow and timing, and reported outcomes. A complete list of data extraction items is presented in **Table 2**.

Quality Assessment

We used the Quality Assessment of Diagnostic Accuracy Studies 2 (QUADAS-2) tool [27] to evaluate the methodological quality and applicability of the included studies at the study level. The tool requires assessing the risk of bias in the four domains patient selection, index test, reference standard, and flow and timing. Further, applicability concerns need to be assessed for the first three domains. Judgments are facilitated by answering pre-defined signaling questions with “yes”, “no”, or “unclear” for each domain. The tool was tailored to our review by adding one signaling question and review-specific guidance was provided to facilitate judgments, see **Appendix 3**. The quality assessment of each included study was performed by one researcher. A second researcher verified all judgments. Any disagreements were resolved by consensus. The results were summarized in the text and visualized as table and figure.

Diagnostic Accuracy Measures and Data Synthesis

For each included study, diagnostic sensitivity, diagnostic specificity, positive predictive value (PPV) and negative predictive value (NPV) with corresponding 95% confidence intervals (CIs) were calculated based on the extracted 2x2 tables. Individual study participants were used as the unit of analysis throughout this work. If a study reported repeat testing of individuals only the initial test was included in our analyses. If a study evaluated more than one test in the same study population, we reported all test evaluations, but only one randomly chosen test was included in the meta-analyses to avoid the necessity to adjust for multiplicity.

The meta-analyses were based on recommendations provided in the methodological guideline “Meta-analysis of diagnostic test accuracy studies” by the European Network for Health Technology Assessment (EUnetHTA) [28]. Summary estimates for sensitivity and specificity were derived as follows: if sufficient data was available and the level of heterogeneity allowed meaningful statistical pooling, bivariate meta-analysis with random effects following the approach by Reitsma et al [29–31] was performed. Otherwise, separate univariate meta-analysis was performed. The bivariate approach required a continuity correction to handle zero cells in 2x2 tables. Thus, in studies where zero events were observed in one of the four cells, a continuity correction was applied by adding 0.5 to all four cells.

Depending on the availability of suitable data, subgroup analyses were performed to assess variables that could have an impact on a test’s diagnostic accuracy, such as the study participants’ presence of symptoms prior to testing and the duration of symptoms prior to testing. The influence of the publication status (preprint vs. peer-reviewed article) was evaluated as well as subgroup analyses with respect to the type of test (antigen vs. molecular; most commonly used antigen tests), setting (community vs. hospital-based), sample type ((oro-) nasopharyngeal vs. anterior nasal for index test and reference standard, respectively), end-user (layperson (self-testing) vs. trained staff/health care worker), and RT-

PCR Ct value (cutoff values of 25 and 30). Differences between subgroups were assessed within the bivariate model and tested for statistical significance using the likelihood ratio test between the standard model and the model, which includes the corresponding variable. In the case of few studies in a subgroup analysis, univariate analysis for sensitivity and specificity were performed as sensitivity analysis and results were reported if remarkable differences between bivariate and univariate analysis were observed.

All statistical analyses were performed using the statistical platform R version 4.1.0 [32]. Bivariate meta-analysis was performed, along with the construction of the corresponding figures, with the package “mada” [33], while univariate meta-analysis was performed with the package “meta” [34] and PropCIs [35]. 95% CIs were computed using the approach proposed by Wilson [36].

RESULTS

Study Selection

Overall, 3011 records were retrieved from 5 bibliographic databases. The PRISMA flow diagram is shown in **Figure 1** and outlines the process of identifying relevant studies from different information sources. References that were excluded at the full-text level can be found in **Appendix 4** with the reason for their exclusion. After removing 36 preprint records identified via MEDLINE and 680 duplicate records, 2295 records were screened for eligibility. 2078 records were excluded at the title/abstract level. Full-text publications of 217 records were retrieved for further assessment. 9 studies [37–45] met all eligibility criteria for inclusion. Furthermore, 21 studies [46–66] were identified as eligible for author queries to obtain study data on pediatric subgroups. Authors of 9 studies did not respond to our request for data [46,47,52,53,55,57–59,62]. In 4 cases [49,60,65,66], authors reported that the required number of individuals who tested positive or negative by the reference standard was not reached, and in 1 case [56] no data on age were recorded. Eventually, author

queries led to the inclusion of 8 further studies [48,50,51,54,61,63,64,67] resulting in a total of 17 relevant studies for this review (12 peer-reviewed journal articles and 5 preprints). The full list of included studies is reported in **Table 3**.

Furthermore, we screened 113 records identified from study registries and 323 records identified from other information sources. The search for studies in study registries allowed to identify 4 planned or ongoing and 4 completed studies with no results posted, see **Table 4** for further details. Information retrieval from other information sources included screening 18 records retrieved from the FIND website, 78 records from NICE Evidence Search, 28 records from NICE, and 23 records from reference lists of 6 systematic reviews [8,68–72] identified via searching bibliographic databases. As a result, no additional study that met the inclusion criteria was identified.

Study Characteristics

All 17 included studies (6355 pediatric study participants) evaluated the performance of antigen tests against the reference standard RT-PCR. The main study characteristics for each individual study are summarized in **Table 5**, further details are reported in **Table 6** and **Table 7**. While 14 studies evaluated the test performance in mixed-age populations, including 24 to 928 pediatric study participants, 3 studies with a sample size between 440 and 1620 individuals exclusively recruited children. In 8 studies, the purpose of testing included diagnostic testing of symptomatic individuals suggestive of SARS-CoV-2 infection. 6 studies reported the inclusion of asymptomatic individuals at an increased risk of infection due to previous exposure to SARS-CoV-2. Here, “asymptomatic” refers to any individual who is healthy, infected but pre-symptomatic or infected but without symptoms. Evaluating the performance of antigen tests in a screening setting (e.g. community mass testing) was the main objective of 6 studies. 7 antigen tests (5 lateral flow immunochromatographic assays and 2 fluorescent immunoassays) from 5 different brands were used in 18 test evaluations, whereas antigen tests by Abbott were most investigated (Panbio COVID-19 Ag Rapid Test n=6, BinaxNOW COVID-19 Ag Card n=5). In more than half of the test evaluations (n=11),

nasopharyngeal samples were collected for the index test. 6 test evaluations used anterior nasal specimens for the index test. In all studies, the reference standard was RT-PCR performed in a laboratory setting.

Risk of Bias and Applicability

The results of the quality assessment are summarized in **Table 8** and **Figure 2**. Quality among studies varied. Only 1 study was at low risk of bias in all four domains of the QUADAS-2 tool. For patient selection, more than half of the studies were at high (n=1) or unclear (n=12) risk of bias because inadequate exclusion of participants occurred, or it was not clear whether a consecutive or random sample was enrolled into the study. All but 1 study was judged as having an unclear risk of bias for the reference standard due to insufficient reporting of blinding. Risk of bias in the flow and timing domain was high in 3 studies due to more than 5% of missing outcome data.

Overall applicability concerns were high in 3 studies due to high concerns in either the patient selection or index test domain. 3 studies were of low concern and the remaining 11 were rated unclear due to insufficient reporting in at least 1 domain.

Results of Individual Studies

RT-PCR positivity rate, diagnostic sensitivity, diagnostic specificity as well as PPV and NPV (and their 95% CIs) of individual studies based on data from 2x2 contingency tables for pediatric populations are reported in **Table 9** and **Figure 3**. The RT-PCR positivity rate, which corresponds to the SARS-CoV-2 prevalence in the sample population, varied between 4.1% and 50%, with a median of 14,5% over n=17 studies. The sensitivity and specificity ranged from 33.3% to 85.7% and 91.7% to 100%, respectively. PPV and NPV ranged from 60.0% to 98.7% and 73.3% to 98.9%, respectively.

For individual studies, separate analyses for subgroups based on symptom status are reported in **Tables 10-12 Figure 4**. Here, populations were defined as symptomatic or asymptomatic if at least 80% of pediatric study participants were reported as being

symptomatic or asymptomatic, respectively. Mixed populations refer to populations with no predominant symptom status. RT-PCR positivity rates of the primary analysis population and the different subgroups based on symptom status are presented in **Figure 5.** 2 studies [51,54] were performed in high-prevalence populations with RT-PCR positivity rates of 38.7% and 50.0%, respectively. The median RT-PCR positivity rate was 13.2% (n=10 test evaluations) in asymptomatic populations, 13.8% in mixed populations (n=3 test evaluations), and 25.7% in symptomatic populations (n=13 test evaluations). Thus, we observed a slight trend in the RT-PCR positivity rate with respect to the proportion of symptomatic subjects. Although the bivariate meta-analysis might be influenced by the difference in the prevalence [73], we did not directly analyze the impact of the prevalence within the bivariate model. Instead, we performed a subgroup analysis with respect to symptom status (see below).

Synthesis of Results

In our primary meta-analyses, we used data from 17 studies evaluating the diagnostic accuracy of antigen tests in pediatric participants. Estimated pooled sensitivity and specificity were 64.2% (95% CI: 57.4%-70.5%) and 99.1% (95% CI: 98.2%-99.5%), respectively. While the estimates for the sensitivity revealed high heterogeneity and thus justified the application of the bivariate model with random effects, the estimates for the specificity were limited to a small range, as shown in **Figure 6**. As a consequence, the estimated summary receiver operating characteristic (SROC) curve cannot be meaningfully interpreted. As pre-specified in the protocol, we performed subgroup analysis evaluating the diagnostic accuracy according to symptom status. Estimated pooled sensitivity and specificity in asymptomatic children was 56.2% (95% CI: 47.6%-64.4%) and 98.6% (95% CI: 97.3%-99.3%), respectively, based on data from 2439 asymptomatic children in 10 studies. Estimated pooled sensitivity and specificity in symptomatic children was 71.8% (95% CI: 63.6%-78.8%) and 98.7% (95% CI: 96.6%-99.5%), respectively, based on data from 3413 symptomatic children in 13 studies. Estimated pooled sensitivity and specificity in the mixed population of

symptomatic and asymptomatic children from 3 studies including 419 children was 63.4% (95% CI: 37.3%-83.5%) and 98.7% (95% CI: 90.8%-99.8%), respectively. The corresponding SROC curves are shown in **Figure 7**. The likelihood ratio test (LRT) for differences between the three groups revealed a p-value of p_{LRT}=0.066. Results for the other subgroup analyses did not show relevant differences in the pooled estimates (setting p_{LRT}=0.400; index test sample type p_{LRT}=0.303; reference standard sample type p_{LRT}=0.723; RT-PCR Ct cutoff value p_{LRT}=0.105; publication status p_{LRT}=0.551; test type (most used) p_{LRT}=0.146). Due to insufficient data, we did not perform subgroup analysis with respect to test type (antigen vs. molecular) and end-user (layperson (self-testing) vs. trained staff/health care worker). Except for 1 study [61,74] where the testing procedure involved (supervised) self-collection of samples by study participants, in all other studies, testing was conducted with trained staff and/or health care workers (if reported). Univariate meta-analysis with random effects for sensitivity and specificity in cases where only a few studies were included (mixed population of symptomatic and asymptomatic children) did not show remarkable differences to the bivariate analysis. The results of all bivariate meta-analyses are summarized in **Table 15**.

DISCUSSION

To our knowledge, this is the first systematic review that focused on evaluating the diagnostic accuracy of rapid point-of-care tests for current SARS-CoV-2 infections in pediatric populations. Our current review comprises 17 studies with 18 evaluations of 7 different antigen tests in children, whereas comprehensive author queries allowed us to include 8 studies that did not provide sufficient data on pediatric study participants in their original study publication. We did not identify any evaluations of molecular-based tests that met our inclusion criteria confirming the current dominant role of antigen tests for rapid point-of-care usage.

Sensitivity estimates of antigen tests varied broadly between studies and were substantially lower as reported by manufacturers. Less variation and only minor discrepancies to performance claims by manufacturers were observed for specificity estimates across studies. Taking into account test-specific pooled results, no test included in this review fully satisfied the minimum performance requirements as recommended by the WHO [9] (minimum sensitivity of ≥ 80% and minimum specificity of ≥ 97%), the US FDA [10] (minimum sensitivity of ≥ 80%, whereas a lower bound of the two-sided 95% CI above 70% is required for over-the-counter use self-tests [75]) or the Medicines & Healthcare products Regulatory Agency (MHRA) in the United Kingdom (UK) [76] (minimum acceptable sensitivity of ≥ 80% with two-sided 95% CI entirely above 70% and minimum acceptable specificity of 95% with two-sided 95% CI entirely above 90%).

While specificities were similar high in symptomatic (98.7% with 95% CI: 96.6%-99.5%) and asymptomatic (98.6% with 95% CI: 97.3%-99.3%) populations, we observed a drop in sensitivity by about 15 percentage points in asymptomatic populations (56.2% with 95% CI: 47.6%-64.4%) compared to symptomatic populations (71.8% with 95% CI 63.6%-78.8%). The better performance in symptomatic populations might be explained by changes in the viral load over the course of infection and the timing of the test: most symptomatic individuals were tested within 7 days of symptom onset in contrast to asymptomatic individuals with more variable disease onset, including individuals in the early (pre-symptomatic) or late stages of infection when viral loads are relatively low [77]. Further, since test performance can also be influenced by prevalence, one should note that median prevalence in symptomatic study populations was about 12 percentage points higher than in asymptomatic study populations.

As expected, the sensitivity increased when the positivity threshold of the reference standard was set to a lower Ct cutoff value of 30 or 25. However, such analyses should not be over-interpreted since Ct values are not standardized across systems or laboratories, making it difficult to directly compare results between different studies. Furthermore, while the Ct value

from RT-PCR is a strong indicator of viral load, there is no specific cutoff viral load which allows distinguishing individuals as being infectious or not. As shown in **Table 13** and **Table 14**, an increase in sensitivity comes at the cost of a decrease in specificity as antigen tests also identify individuals with moderate or low viral loads, who would then be considered as false positives.

Despite some methodological differences (such as the stringency of inclusion criteria) and neglecting differences between included studies (e.g. settings), the findings of our review are similar to those in the recent Cochrane Review by Dinnes et al. [8]. These similarities between pediatric and adult populations might be explained by the findings by Jones et al. [78], who only identified minor differences in viral loads across age groups in a comprehensive analysis of more than 25,000 individuals who tested positive for SARS-CoV-2 by RT-PCR.

For the current version of our review, publication bias is not considered as relevant due to the novelty of the topic. Non-publication of studies, in particular underreporting of studies with unfavorable outcomes, may introduce bias and threaten the validity of systematic reviews. It is now commonly expected to publish results of clinical studies within 12 months of completion [79–81]. No study included in our review was published before November 2020. All 4 completed studies that were identified through searching study registries were completed within the last 9 months. Of note is that for all but 1 study [39] included in our review no entry in a study registry was reported.

Despite the roll-out of vaccines, testing continues to be a key to pandemic control. As experts predict new surges of infections in fall, early identification of outbreaks will remain vital for controlling the spread of SARS-CoV-2, particularly in populations with low vaccination rates. Consequently, multi-layered mitigation strategies will continue involving screening testing of children in schools and kindergarten to avoid further closures. The high specificity of antigen tests and the corresponding PPVs calculated for the pediatric study populations suggest that antigen testing might be a valuable tool to rapidly identify children

with SARS-CoV-2 infection in moderate to high prevalence settings. However, at the same time, it is important to raise awareness that antigen tests should not be used to rule out SARS-CoV-2 infection (or infectiousness) due to their limited sensitivity. Whether increasing the frequency of antigen-based testing leads to an improved overall diagnostic accuracy that allows to effectively reduce transmission of SARS-CoV-2, has yet to be demonstrated in practice [82]. The latter two aspects and the urgent need for high quality screening tests likely led to the recent publication of a new target product profile by the MHRA in the UK [83], which includes increased performance requirements for self-tests to be used in national testing programs that aim at detecting current SARS-CoV-2 infections in individuals without symptoms. Here, the minimum acceptable sensitivity for tests to “rule out” a current infection is ≥97% with two-sided 95% CI entirely above 95%. The minimum acceptable specificity is ≥99.5% with two-sided 95% CI entirely above 97%. Further, it is stated that performance claims of repeated testing strategies require adequate clinical evidence rather than evidence from modelling studies only.

Other screening testing methods such as molecular-based pool testing, which involves RT-PCR testing of pooled samples and so-called deconvolution testing of individuals belonging to pools tested positive are currently under investigation [84,85] and may complement mere antigen testing, in particular in low prevalence settings. Further, novel tests, for example, lateral flow tests based on clustered regularly interspaced short palindromic repeat (CRISPR), hold great promise for a highly sensitive direct detection of SARS-CoV-2 [86] but have yet to demonstrate their value upon market access.

Limitations

The results presented in this review should be considered in light of the following limitations: 1) As visualized in the QUADAS-2 summary graph, the majority of studies were at unclear risk of bias in at least three of the four domains of the QUADAS-2 tool because of poor reporting by authors. Therefore, the results reported in this review should be interpreted with caution. The issue of insufficient reporting has been addressed previously and led to the

publication of comprehensive guidance to authors evaluating the clinical performance of tests for SARS-CoV-2 [87]. 2) We acknowledge that infectiousness as target condition is of higher practical relevance than current SARS-CoV-2 infection, which was chosen as the target condition of this review. While RT-PCR as the corresponding reference standard is a highly sensitive method that is used to detect the presence of viral ribonucleic acid (RNA) in a specimen, this does not necessarily indicate that infectious virus is present. Therefore, the actual transmission risk from individuals who tested RT-PCR positive remains unknown. Testing for infectiousness would allow to identify (and isolate) exclusively individuals who could pass the virus to others. However, while there have been attempts to use viral load (estimated from Ct values) or virus viability in cell culture as a proxy to determine infectious individuals, up to now, there is no adequate reference standard for infectiousness [82]. 3) Screening testing programs of children in schools and kindergarten using antigen tests have been implemented in many countries. Specific aspects that define these use cases, such as sample collection in toddlers by laypersons or self-testing in schools performed by children, are likely to influence the real-life test performance but were not addressed in any of the studies included in our review. Furthermore, one should keep in mind that diagnostic accuracy is only one factor affecting the effectiveness of testing programs [88]. 4) Only 7 different antigen tests were included in our review, and 4 of these were only evaluated in 1 study each. Thus, the performance of most antigen tests under real-life conditions remains unknown. While the number of antigen tests is still small in the US due to more rigorous approval processes, the situation in Europe is different, since the current regulatory framework for market access in the Europe Union (EU) [89] allows self-declaration of regulatory conformity of SARS-CoV-2 antigen tests for professional use by manufacturers without the involvement of a third party. As of July 6, 2021, more than 500 antigen tests gained market access in the EU [90]. A recent laboratory-based study evaluated the sensitivity of 122 of these antigen tests using common SARS-CoV-2 specimens with varying viral concentrations [91]. Even under such ideal conditions, a wide range of sensitivities was observed, whereas 26 tests missed the study's sensitivity criteria of 75% for specimens with

high SARS-CoV-2 concentrations of around 10^6 SARS-CoV-2 RNA/ml and higher corresponding to a Ct value of <25. 5) Diagnostic accuracy estimates reported in this review may not apply to future variants of SARS-CoV-2. Considering the reported recruitment periods, most individuals identified as RT-PCR positive were likely infected with the wild-type of SARS-CoV-2. The impact of new emerging variants of SARS-CoV-2 on the diagnostic accuracy of SARS-CoV-2 tests is unknown and requires thorough investigation.

CONCLUSION

Our findings confirm the urgent need for independent validations of rapid tests in pediatric populations under real-life conditions. Estimates of sensitivity and specificity and their 95% CIs from the bivariate meta-analyses indicate a subpar real-life performance of current antigen tests below the minimum performance criteria set by WHO, the US FDA, or the MHRA in the UK. Policymakers should especially be aware of the limited diagnostic sensitivity of current antigen tests and should require performance data from diagnostic accuracy studies in the intended use setting prior to the broad implementation of testing programs. Results presented in this systematic review should be interpreted with caution since risk of bias was predominantly judged as unclear due to poor reporting. We encourage study authors to put more emphasis on the reporting of their studies as stronger adherence to reporting standards would highly increase the value of their research. Future studies should investigate whether screening testing in pediatric populations is indeed effective in reducing the spread of SARS-CoV-2 and whether the benefits outweigh the harms.

ACKNOWLEDGMENTS

We thank Dr. Siw Waffenschmidt (IQWiG, Germany) for her valuable guidance during the development of the search strategies, the peer-review of the final search strategy, and the literature screening technical support. Further, we are grateful to all study authors who

replied to our author queries and who provided us with separate data on the pediatric study participants included in their studies.

REFERENCES

[1] Crozier A, Rajan S, Buchan I, McKee M. Put to the test: use of rapid testing technologies for covid-19. BMJ 2021;372:n208. https://doi.org/10.1136/bmj.n208.

[2] Guglielmi G. Fast coronavirus tests: what they can and can't do. Nature 2020;585:496–8. https://doi.org/10.1038/d41586-020-02661-2.

[3] Mina MJ, Parker R, Larremore DB. Rethinking Covid-19 Test Sensitivity — A Strategy for Containment. N Engl J Med 2020;383:e120. https://doi.org/10.1056/NEJMp2025631.

[4] Kmietowicz Z. Covid-19: Controversial rapid test policy divides doctors and scientists. BMJ 2021;372. https://doi.org/10.1136/bmj.n81.

[5] Larremore DB, Wilder B, Lester E, Shehata S, Burke JM, Hay JA, et al. Test sensitivity is secondary to frequency and turnaround time for COVID-19 screening. Sci Adv 2021;7. https://doi.org/10.1126/sciadv.abd5393.

[6] Moreno GK, Braun KM, Pray IW, Segaloff HE, Lim A, Poulsen K, et al. SARS-CoV-2 transmission in intercollegiate athletics not fully mitigated with daily antigen testing. Clin Infect Dis Off Publ Infect Dis Soc Am 2021. https://doi.org/10.1093/cid/ciab343.

[7] CDC. Interim Guidance for Antigen Testing for SARS-CoV-2. Cent Dis Control Prev 2021. https://www.cdc.gov/coronavirus/2019-ncov/lab/resources/antigen-tests-guidelines.html (accessed June 12, 2021).

[8] Dinnes J, Deeks JJ, Berhane S, Taylor M, Adriano A, Davenport C, et al. Rapid, point-of-care antigen and molecular-based tests for diagnosis of SARS-CoV-2 infection. Cochrane Database Syst Rev 2021;2021. https://doi.org/10.1002/14651858.CD013705.pub2.

[9] Emergency Prepardness, WHO Headquarters, editor. Antigen-detection in the diagnosis of SARS-CoV-2 infection using rapid immunoassays. Interim guidance 2020.

[10] U.S. Food and Drug Administration, Antigen Template for Test Developers 2020. https://www.fda.gov/media/137907/download (accessed June 12, 2021).

[11] Torjesen I. What do we know about lateral flow tests and mass testing in schools? BMJ 2021;372:n706. https://doi.org/10.1136/bmj.n706.

[12] Fujita-Rohwerder N, Zens Y, Beckmann L, Verma A. Diagnostic accuracy of rapid point-of-care tests for diagnosis of current SARS-CoV-2 infections in children: A systematic review. PROSPERO 2021 CRD42021236313 2021. https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=236313 (accessed June 12, 2021).

[13] Salameh J-P, Bossuyt PM, McGrath TA, Thombs BD, Hyde CJ, Macaskill P, et al. Preferred reporting items for systematic review and meta-analysis of diagnostic test accuracy studies (PRISMA-DTA): explanation, elaboration, and checklist. BMJ 2020;370:m2632. https://doi.org/10.1136/bmj.m2632.

[14] Cohen JF, Deeks JJ, Hooft L, Salameh J-P, Korevaar DA, Gatsonis C, et al. Preferred reporting items for journal and conference abstracts of systematic reviews and meta-analyses of diagnostic test accuracy studies (PRISMA-DTA for Abstracts): checklist, explanation, and elaboration. BMJ 2021;372:n265. https://doi.org/10.1136/bmj.n265.

[15] Rethlefsen ML, Kirtley S, Waffenschmidt S, Ayala AP, Moher D, Page MJ, et al. PRISMA-S: an extension to the PRISMA Statement for Reporting Literature Searches in Systematic Reviews. Syst Rev 2021;10:39. https://doi.org/10.1186/s13643-020-01542-z.

[16] Rutjes AWS. Evidence of bias and variation in diagnostic accuracy studies. Can Med Assoc J 2006;174:469–76. https://doi.org/10.1503/cmaj.050090.

[17] Deeks JJ, Dinnes J, Takwoingi Y, Davenport C, Spijker R, Taylor-Phillips S, et al. Antibody tests for identification of current and past infection with SARS-CoV-2. Cochrane Database Syst Rev 2020;6:CD013652. https://doi.org/10.1002/14651858.CD013652.

[18] Bossuyt PM, Reitsma JB, Bruns DE, Gatsonis CA, Glasziou PP, Irwig L, et al. STARD 2015: an updated list of essential items for reporting diagnostic accuracy studies. BMJ 2015;351:h5527. https://doi.org/10.1136/bmj.h5527.

[19] National Institute for Health and Care Excellence. Evidence standards framework for SARS-CoV-2 and anti-SARS-CoV-2 antibody diagnostic tests 2020.

[20] Hamelers A, Parkin M. A full text collection of COVID-19 preprints in Europe PMC using JATS XML. National Center for Biotechnology Information (US); 2021.

[21] de Vet H, Eisinga A, Riphagen I, Aertgeerts B, Pewsner D. Chapter 7: Searching for Studies. Cochrane Handb. Syst. Rev. Diagn. Test Accuracy. Version 0.4 [updated September 2008], The Cochrane Collaboration; 2008.

[22] Hausner E, Waffenschmidt S, Kaiser T, Simon M. Routine development of objectively derived search strategies. Syst Rev 2012;1:19. https://doi.org/10.1186/2046-4053-1-19.

[23] Benoit K, Watanabe K, Wang H, Nulty P, Obeng A, Müller S, et al. quanteda: An R package for the quantitative analysis of textual data. J Open Source Softw 2018;3:774. https://doi.org/10.21105/joss.00774.

[24] Heidelberg University Hospital. Rapid antigen tests for the diagnosis of a SARS-CoV-2 infection. Diagn Glob Health n.d. https://www.klinikum.uni-heidelberg.de/en/diagnostics-global-health.

[25] McGowan J, Sampson M, Salzwedel DM, Cogo E, Foerster V, Lefebvre C. PRESS Peer Review of Electronic Search Strategies: 2015 Guideline Statement. J Clin Epidemiol 2016;75:40–6. https://doi.org/10.1016/j.jclinepi.2016.01.021.

[26] Hausner E, Ebrahim S, Herrmann-Frank A, Janzen T, Kerekes M, Pischedda M, Waffenschmidt S, Kaiser T. Study selection by means of a web-based Trial Selection DataBase (webTSDB). Abstr. 19th Cochrane Colloq., Madrid, Spain: John Wiley & Sons; 2011.

[27] Whiting PF, Rutjes AWS, Westwood ME, Mallett S, Deeks JJ, Reitsma JB, et al. QUADAS-2: A Revised Tool for the Quality Assessment of Diagnostic Accuracy

Studies. Ann Intern Med 2011;155:529–36. https://doi.org/10.7326/0003-4819-155-8-201110180-00009.

[28] European Network for Health Technology Assessment (EUnetHTA). Meta-analysis of Diagnostic Test Accuracy Studies 2014. https://eunethta.eu/wp-content/uploads/2018/01/Meta-analysis-of-Diagnostic-Test-Accuracy-Studies_Guideline_Final-Nov-2014.pdf (accessed January 10, 2021).

[29] Rutter CM, Gatsonis CA. A hierarchical regression approach to meta-analysis of diagnostic test accuracy evaluations. Stat Med 2001;20:2865–84. https://doi.org/10.1002/sim.942.

[30] Reitsma JB, Glas AS, Rutjes AWS, Scholten RJPM, Bossuyt PM, Zwinderman AH. Bivariate analysis of sensitivity and specificity produces informative summary measures in diagnostic reviews. J Clin Epidemiol 2005;58:982–90. https://doi.org/10.1016/j.jclinepi.2005.02.022.

[31] Harbord RM, Deeks JJ, Egger M, Whiting P, Sterne JAC. A unification of models for meta-analysis of diagnostic accuracy studies. Biostat Oxf Engl 2007;8:239–51. https://doi.org/10.1093/biostatistics/kxl004.

[32] R Core Team. R: A Language and Environment for Statistical Computing 2021. https://www.R-project.org (accessed June 10, 2021).

[33] Doebler, Philipp. mada: Meta-Analysis of Diagnostic Accuracy, Version 0.5.10 2020. https://CRAN.R-project.org/package=mada (accessed July 10, 2021).

[34] Balduzzi S, Rücker G, Schwarzer G. How to perform a meta-analysis with R: a practical tutorial. Evid Based Ment Health 2019;22:153–60. https://doi.org/10.1136/ebmental-2019-300117.

[35] Scherer R. PropCIs: Various Confidence Interval Methods for Proportions 2018. https://cran.r-project.org/package=PropCIs (accessed July 10, 2021).

[36] Wilson EB. Probable Inference, the Law of Succession, and Statistical Inference. J Am Stat Assoc 1927;22:209–12. https://doi.org/10.1080/01621459.1927.10502953.

[37] Gonzalez-Donapetry P, Garcia-Clemente P, Bloise I, Garcia-Sanchez C, Sanchez Castellano MA, Romero MP, et al. Think of the Children: Evaluation of SARS-CoV-2 Rapid Antigen Test in Pediatric Population. Pediatr Infect Dis J 2021. https://doi.org/10.1097/INF.0000000000003101.

[38] L'Huillier A, Lacour M, Sadiku D, Gadiri MA, Siebenthal LD, Schibler M, et al. Diagnostic accuracy of SARS-CoV-2 rapid antigen detection testing in symptomatic and asymptomatic children in the clinical setting. MedRxiv 2021:2021.04.15.21255577. https://doi.org/10.1101/2021.04.15.21255577.

[39] Möckel M, Corman VM, Stegemann MS, Hofmann J, Stein A, Jones TC, et al. SARS-CoV-2 Antigen Rapid Immunoassay for Diagnosis of COVID-19 in the Emergency Department. Biomark Biochem Indic Expo Response Susceptibility Chem 2021:1–13. https://doi.org/10.1080/1354750X.2021.1876769.

[40] Pilarowski G, Marquez C, Rubio L, Peng J, Martinez J, Black D, et al. Field performance and public health response using the BinaxNOW TM Rapid SARS-CoV-2 antigen detection assay during community-based testing. Clin Infect Dis Off Publ Infect Dis Soc Am 2020. https://doi.org/10.1093/cid/ciaa1890.

[41] Pollock NR, Jacobs JR, Tran K, Cranston AE, Smith S, O'Kane CY, et al. Performance and Implementation Evaluation of the Abbott BinaxNOW Rapid Antigen Test in a High-throughput Drive-through Community Testing Site in Massachusetts. J Clin Microbiol 2021. https://doi.org/10.1128/JCM.00083-21.

[42] Pollock NR, Tran K, Jacobs JR, Cranston AE, Smith S, O'Kane CY, et al. Performance and Operational Evaluation of the Access Bio CareStart Rapid Antigen Test in a High-throughput Drive-through Community Testing Site in Massachusetts. MedRxiv 2021:2021.03.07.21253101. https://doi.org/10.1101/2021.03.07.21253101.

[43] Prince-Guerra J.L., Almendares O., Nolen L.D., Gunn J.K.L., Dale A.P., Buono S.A., et al. Evaluation of Abbott BinaxNOW Rapid Antigen Test for SARS-CoV-2 Infection at Two Community-Based Testing Sites - Pima County, Arizona, November 3-17, 2020.

MMWR Morb Mortal Wkly Rep 2021;70:100–5. https://doi.org/10.15585/mmwr.mm7003e3.

[44] Sood N, Shetgiri R, Rodriguez A, Jimenez D, Treminino S, Daflos A, et al. Evaluation of the Abbott BinaxNOW rapid antigen test for SARS-CoV-2 infection in children: Implications for screening in a school setting. PloS One 2021;16:e0249710. https://doi.org/10.1371/journal.pone.0249710.

[45] Villaverde S, Domínguez-Rodríguez S, Sabrido G, Pérez-Jorge C, Plata M, Romero MP, et al. Diagnostic Accuracy of the Panbio Severe Acute Respiratory Syndrome Coronavirus 2 Antigen Rapid Test Compared with Reverse-Transcriptase Polymerase Chain Reaction Testing of Nasopharyngeal Samples in the Pediatric Population. J Pediatr 2021;232:287-289.e4. https://doi.org/10.1016/j.jpeds.2021.01.027.

[46] Abdulrahman A, Mustafa F, AlAwadhi AI, Alansari Q, AlAlawi B, AlQahtani M. Comparison of SARS-COV-2 nasal antigen test to nasopharyngeal RT-PCR in mildly symptomatic patients. MedRxiv 2020:2020.11.10.20228973. https://doi.org/10.1101/2020.11.10.20228973.

[47] Agulló V, Fernández-González M, Ortiz de la Tabla V, Gonzalo-Jiménez N, García JA, Masiá M, et al. Evaluation of the rapid antigen test Panbio COVID-19 in saliva and nasal swabs in a population-based point-of-care study. J Infect 2021;82:186–230. https://doi.org/10.1016/j.jinf.2020.12.007.

[48] Akingba OL, Sprong K, Hardie DR. Field performance evaluation of the PanBio rapid SARS-CoV-2 antigen assay in an epidemic driven by 501Y.v2 (lineage B.1.351) in the Eastern Cape, South Africa. MedRxiv 2021:2021.02.03.21251057. https://doi.org/10.1101/2021.02.03.21251057.

[49] Berger A, Nsoga MTN, Perez-Rodriguez FJ, Aad YA, Sattonnet-Roche P, Gayet-Ageron A, et al. Diagnostic accuracy of two commercial SARS-CoV-2 Antigen-detecting rapid tests at the point of care in community-based testing centers. MedRxiv 2020:2020.11.20.20235341. https://doi.org/10.1101/2020.11.20.20235341.

[50] Bianco G, Boattini M, Barbui AM, Scozzari G, Riccardini F, Coggiola M, et al. Evaluation of an antigen-based test for hospital point-of-care diagnosis of SARS-CoV-2 infection. J Clin Virol 2021;139:104838. https://doi.org/10.1016/j.jcv.2021.104838.

[51] Drevinek P, Hurych J, Kepka Z, Briksi A, Kulich M, Zajac M, et al. The sensitivity of SARS-CoV-2 antigen tests in the view of large-scale testing. MedRxiv 2020:2020.11.23.20237198. https://doi.org/10.1101/2020.11.23.20237198.

[52] Favresse J, Gillot C, Oliveira M, Cadrobbi J, Elsen M, Eucher C, et al. Head-to-Head Comparison of Rapid and Automated Antigen Detection Tests for the Diagnosis of SARS-CoV-2 Infection. J Clin Med 2021;10. https://doi.org/10.3390/jcm10020265.

[53] Fournier P-E, Zandotti C, Ninove L, Prudent E, Colson P, Gazin C, et al. Contribution of VitaPCR SARS-CoV-2 to the emergency diagnosis of COVID-19. J Clin Virol Off Publ Pan Am Soc Clin Virol 2020;133:104682. https://doi.org/10.1016/j.jcv.2020.104682.

[54] Homza M, Zelena H, Janosek J, Tomaskova H, Jezo E, Kloudova A, et al. Covid-19 antigen testing: better than we know? A test accuracy study. Infect Dis Lond Engl n.d.:1–8. https://doi.org/10.1080/23744235.2021.1914857.

[55] Kilic A, Hiestand B, Palavecino E. Evaluation of Performance of the BD Veritor SARS-CoV-2 Chromatographic Immunoassay Test in Patients with Symptoms of COVID-19. J Clin Microbiol 2021;59. https://doi.org/10.1128/JCM.00260-21.

[56] Landaas ET, Storm ML, Tollånes MC, Barlinn R, Kran A-MB, Bragstad K, et al. Diagnostic performance of a SARS-CoV-2 rapid antigen test in a large, Norwegian cohort. J Clin Virol Off Publ Pan Am Soc Clin Virol 2021;137:104789. https://doi.org/10.1016/j.jcv.2021.104789.

[57] Marti JLG, Gribschaw J, McCullough M, Mallon A, Acero J, Kinzler A, et al. Differences in detected viral loads guide use of SARS-CoV-2 antigen-detection assays towards symptomatic college students and children. MedRxiv 2021:2021.01.28.21250365. https://doi.org/10.1101/2021.01.28.21250365.

[58] Masia M, Fernandez-Gonzalez M, Sanchez M, Carvajal M, Garcia JA, Gonzalo-Jimenez N, et al. Nasopharyngeal Panbio COVID-19 Antigen Performed at Point-of-

Care Has a High Sensitivity in Symptomatic and Asymptomatic Patients With Higher Risk for Transmission and Older Age. Open Forum Infect Dis 2021;8:ofab059. https://doi.org/10.1093/ofid/ofab059.

[59] Merino P, Guinea J, Muñoz-Gallego I, González-Donapetry P, Galán JC, Antona N, et al. Multicenter evaluation of the Panbio™ COVID-19 rapid antigen-detection test for the diagnosis of SARS-CoV-2 infection. Clin Microbiol Infect Off Publ Eur Soc Clin Microbiol Infect Dis 2021. https://doi.org/10.1016/j.cmi.2021.02.001.

[60] Nsoga MTN, Kronig I, Rodriguez FJP, Sattonnet-Roche P, Silva DD, Helbling J, et al. Diagnostic accuracy of Panbio™ rapid antigen tests on oropharyngeal swabs for detection of SARS-CoV-2. MedRxiv 2021:2021.01.30.21250314. https://doi.org/10.1101/2021.01.30.21250314.

[61] Shah MM, Salvatore PP, Ford L, Kamitani E, Whaley MJ, Kaitlin M, et al. Performance of Repeat BinaxNOW SARS-CoV-2 Antigen Testing in a Community Setting, Wisconsin, November-December 2020. Clin Infect Dis Off Publ Infect Dis Soc Am 2021. https://doi.org/10.1093/cid/ciab309.

[62] Shrestha B, Neupane AK, Pant S, Shrestha A, Bastola A, Rajbhandari B, et al. Sensitivity and Specificity of Lateral Flow Antigen Test Kits for COVID-19 in Asymptomatic Population of Quarantine Centre of Province 3. Kathmandu Univ Med J KUMJ 2020;18:36–9.

[63] Takeuchi Y, Akashi Y, Kato D, Kuwahara M, Muramatsu S, Ueda A, et al. The evaluation of a newly developed antigen test (QuickNavi™-COVID19 Ag) for SARS-CoV-2: A prospective observational study in Japan. J Infect Chemother 2021;27:890–4. https://doi.org/10.1016/j.jiac.2021.02.029.

[64] Torres I, Poujois S, Albert E, Colomina J, Navarro D. Evaluation of a rapid antigen test (Panbio™ COVID-19 Ag rapid test device) for SARS-CoV-2 detection in asymptomatic close contacts of COVID-19 patients. Clin Microbiol Infect 2021;27:636.e1-636.e4. https://doi.org/10.1016/j.cmi.2020.12.022.

[65] Torres I, Poujois S, Albert E, Alvarez G, Colomina J, Navarro D. Point-of-care evaluation of a rapid antigen test (CLINITEST R Rapid COVID-19 Antigen Test) for diagnosis of SARS-CoV-2 infection in symptomatic and asymptomatic individuals. J Infect 2021. https://doi.org/10.1016/j.jinf.2021.02.010.

[66] Turcato G, Zaboli A, Pfeifer N, Ciccariello L, Sibilio S, Tezza G, et al. Clinical application of a rapid antigen test for the detection of SARS-CoV-2 infection in symptomatic and asymptomatic patients evaluated in the emergency department: A preliminary report. J Infect 2021;82:e14–6. https://doi.org/10.1016/j.jinf.2020.12.012.

[67] Kiyasu Y, Takeuchi Y, Akashi Y, Kato D, Kuwahara M, Muramatsu S, et al. Prospective analytical performance evaluation of the QuickNavi™-COVID19 Ag for asymptomatic individuals. MedRxiv 2021:2021.04.01.21254813. https://doi.org/10.1101/2021.04.01.21254813.

[68] Brümmer LE, Katzenschlager S, Gaeddert M, Erdmann C, Schmitz S, Bota M, et al. The accuracy of novel antigen rapid diagnostics for SARS-CoV-2: a living systematic review and meta-analysis. MedRxiv 2021:2021.02.26.21252546. https://doi.org/10.1101/2021.02.26.21252546.

[69] Lee J, Song J-U. Diagnostic accuracy of the Cepheid Xpert Xpress and the Abbott ID NOW assay for rapid detection of SARS-CoV-2: A systematic review and meta-analysis. J Med Virol 2021;93:4523–31. https://doi.org/10.1002/jmv.26994.

[70] Mustafa Hellou M., Gorska A., Mazzaferri F., Cremonini E., Gentilotti E., De Nardo P., et al. Nucleic acid amplification tests on respiratory samples for the diagnosis of coronavirus infections: a systematic review and meta-analysis. Clin Microbiol Infect 2021;27:341–51. https://doi.org/10.1016/j.cmi.2020.11.002.

[71] Yong Chua PE, Gwee SXW, Wang MX, Hao G, Pang J. SARS-CoV-2 Diagnostic Tests for Reopening of Borders: A Systematic Review and Meta-Analysis. SSRN 2021. https://doi.org/10.2139/ssrn.3774144.

[72] Yoon SH, Yang S, Cho H, Eun S, Koo CM, Kim MK. Point-of-care testing for the detection of SARS-CoV-2: a systematic review and meta-analysis. Eur Rev Med Pharmacol Sci 2021;25:503–17. https://doi.org/10.26355/eurrev_202101_24422.

[73] Hoyer A, Kuss O. Meta-analysis of diagnostic tests accounting for disease prevalence: a new model using trivariate copulas. Stat Med 2015;34:1912–24. https://doi.org/10.1002/sim.6463.

[74] Ford L, Whaley MJ, Shah MM, Salvatore PP, Segaloff HE, Delaney A, et al. Characteristics of children and antigen test performance at a SARS-CoV-2 community testing site. MedRxiv 2021:2021.07.06.21259792. https://doi.org/10.1101/2021.07.06.21259792.

[75] Food and Drug Administration (FDA). Supplemental Template for Developers of Molecular and Antigen Diagnostic COVID-19 Tests for Screening with Serial Testing 2021. https://www.fda.gov/media/146695/download (accessed June 26, 2021).

[76] Medicines & Healthcare products Regulatory Agency (MHRA). Target Product Profile: Point of Care SARS-CoV-2 detection tests. Target Prod Profile Point Care SARS-CoV-2 Detect Tests n.d. https://www.gov.uk/government/publications/how-tests-and-testing-kits-for-coronavirus-covid-19-work/target-product-profile-point-of-care-sars-cov-2-detection-tests (accessed June 27, 2021).

[77] Walsh KA, Jordan K, Clyne B, Rohde D, Drummond L, Byrne P, et al. SARS-CoV-2 detection, viral load and infectivity over the course of an infection. J Infect 2020;81:357–71. https://doi.org/10.1016/j.jinf.2020.06.067.

[78] Jones TC, Biele G, Mühlemann B, Veith T, Schneider J, Beheim-Schwarzbach J, et al. Estimating infectiousness throughout SARS-CoV-2 infection course. Science 2021:eabi5273. https://doi.org/10.1126/science.abi5273.

[79] Moorthy VS, Karam G, Vannice KS, Kieny M-P. Rationale for WHO's New Position Calling for Prompt Reporting and Public Disclosure of Interventional Clinical Trial Results. PLOS Med 2015;12:e1001819. https://doi.org/10.1371/journal.pmed.1001819.

[80] Reardon S. US toughens rules for clinical-trial transparency. Nature 2016. https://doi.org/10.1038/nature.2016.20616.

[81] Goldacre B, DeVito NJ, Heneghan C, Irving F, Bacon S, Fleminger J, et al. Compliance with requirement to report results on the EU Clinical Trials Register: cohort study and web resource. BMJ 2018;362:k3218. https://doi.org/10.1136/bmj.k3218.

[82] Royal Statistical Society. Diagnostic Tests Working Group Report 2021. https://rss.org.uk/RSS/media/File-library/Policy/2021/RSS-Diagnostic-tests-report-FINAL.pdf (accessed June 10, 2021).

[83] Medicines & Healthcare products Regulatory Agency (MHRA). Target Product Profile: In Vitro Diagnostic (IVD) self-tests for the detection of SARS-CoV-2 in people without symptoms. Target Prod Profile Vitro Diagn IVD Self-Tests Detect SARS-CoV-2 People Symptoms n.d. https://www.gov.uk/government/publications/how-tests-and-testing-kits-for-coronavirus-covid-19-work/target-product-profile-in-vitro-diagnostic-ivd-self-tests-for-the-detection-of-sars-cov-2-in-people-without-symptoms (accessed July 10, 2021).

[84] Pollock NR, Berlin D, Smole SC, Madoff LC, Brown C, Henderson K, et al. Implementation of SARS-CoV2 Screening in K-12 Schools using In-School Pooled Molecular Testing and Deconvolution by Rapid Antigen Test. J Clin Microbiol n.d.;0:JCM.01123-21. https://doi.org/10.1128/JCM.01123-21.

[85] Tsang NNY, So HC, Ng KY, Cowling BJ, Leung GM, Ip DKM. Diagnostic performance of different sampling approaches for SARS-CoV-2 RT-PCR testing: a systematic review and meta-analysis. Lancet Infect Dis 2021. https://doi.org/10.1016/S1473-3099(21)00146-8.

[86] Broughton J.P., Deng X., Yu G., Fasching C.L., Servellita V., Singh J., et al. CRISPR-Cas12-based detection of SARS-CoV-2. Nat Biotechnol 2020;38:870–4. https://doi.org/10.1038/s41587-020-0513-4.

[87] Doust JA, Bell KJL, Leeflang MMG, Dinnes J, Lord SJ, Mallett S, et al. Guidance for the design and reporting of studies evaluating the clinical performance of tests for present or past SARS-CoV-2 infection. BMJ 2021;372:n568. https://doi.org/10.1136/bmj.n568.

[88] Ruffano LF di, Hyde CJ, McCaffery KJ, Bossuyt PMM, Deeks JJ. Assessing the value of diagnostic tests: a framework for designing and evaluating trials. BMJ 2012;344:e686. https://doi.org/10.1136/bmj.e686.

[89] Directive 98/79/EC of the European Parliament and of the Council of 27 October 1998 on in vitro diagnostic medical devices 1998. https://eur-lex.europa.eu/eli/dir/1998/79/oj (accessed July 12, 2021).

[90] Federal Institute for Drugs and Medical Devices (BfArM). List of antigen tests for professional use for direct pathogen detection of the coronavirus SARS-CoV-2 n.d. https://antigentest.bfarm.de/ords/f?p=ANTIGENTESTS-AUF-SARS-COV-2 (accessed July 6, 2021).

[91] Scheiblauer H, Filomena A, Nitsche A, Puyskens A, Corman VM, Drosten C, et al. Comparative sensitivity evaluation for 122 CE-marked SARS-CoV-2 antigen rapid tests. MedRxiv 2021:2021.05.11.21257016. https://doi.org/10.1101/2021.05.11.21257016.



Figure 1: PRISMA Flow diagram illustrating the selection process of primary studies included in this systematic review and meta-analysis.



Figure 2: QUADAS-2 risk of bias and applicability concerns – graphical summary showing the review authors' judgment about each domain as percentages across 18 test evaluations reported in 17 included studies.



Figure 3: Forest plot of sensitivity and specificity of antigen tests in entire paediatric study populations irrespective of symptoms. The point estimates of sensitivity and specificity from each study (identified by name of first author) are shown as squares, the corresponding 95% confidence intervals (95% CIs) are represented as horizontal lines. TP: true positive, FN: false negative, TN: true negative, FP: false positive.



Figure 4: Forest plot of sensitivity and specificity of antigen tests in (a) symptomatic, (b) asymptomatic, and (c) mixed paediatric study populations. The point estimates of sensitivity and specificity from each study (identified by name of first author) are shown as squares, the corresponding 95% confidence intervals (95% CIs) are represented as horizontal lines. TP: true positive, FN: false negative, TN: true negative, FP: false positive.



Figure 5: Box and whisker plots of the RT-PCR positivity rates in entire paediatric study populations irrespective of symptoms and in asymptomatic, mixed, and symptomatic paediatric study populations. The box is drawn from the first to the third quartile, defined via hinges. The bold horizontal line in the box denotes the median. The whiskers extend out of the box by 1.5 times the difference between the hinges. Outliers are plotted as small circle. The width of the box corresponds to the number of considered studies.



Figure 6: Summary receiver operating characteristic (SROC) plot of sensitivity and specificity of antigen tests for diagnosis of current SARS-CoV-2 infections in entire paediatric study populations irrespective of symptoms. Each circle represents the point estimate of an individual study, whereas the size of the circle correlates with the number of paediatric study participants (small circle: <100 participants, medium circle: between 100 and 500 participants, large circle: >500 participants). The pooled estimate (black dot) of the pair of sensitivity (Se) and specificity (Sp) is surrounded by its 95% confidence region (closed curve with short dashes) and prediction region (closed curve with long dashes). The estimation of the SROC curve is based on the bivariate approach by Rutter and Gatsonis [29].



Figure 7: Summary receiver operating characteristic (SROC) plot of sensitivity and specificity of antigen tests for diagnosis of current SARS-CoV-2 infections in (a) symptomatic, (b) asymptomatic, and (c) mixed symptomatic and asymptomatic paediatric study populations. Each circle represents the point estimate of an individual study, whereas the size of the circle correlates with the number of paediatric study participants (small circle: <100 participants, medium circle: between 100 and 500 participants, large circle: >500 participants). The pooled estimate (black dot) of the pair of sensitivity (Se) and specificity (Sp) is surrounded by its 95% confidence region (closed curve with short dashes) and prediction region (closed curve with long dashes). The estimation of the SROC curve is based on the bivariate approach by Rutter and Gatsonis [29].

Table 1: Eligibility criteria for primary studies

(Sub-)Population	Children (i.e. pediatric study participants <18 years of age) • with symptoms suggestive of COVID-19, or • without symptoms, but at an increased risk of infection (e.g. due to recent exposure to SARS-CoV-2 → contact tracing), or • participating in mass testing (e.g. in schools) regardless of symptoms.
Index test	Any rapid point-of-care test that is designed to detect an active SARS-CoV-2 infection and that meets the following criteria: • performed in a non-laboratory setting at or near the point of care (including non-healthcare settings such as schools or community testing sites) • minimal or no training required for end user • sample condition: fresh • time to result ≤ 60 minutes • commercially available
Reference standard	Any validated laboratory-based reverse transcription-polymerase chain reaction (RT-PCR) assay alone or in combination with clinical findings or clinical follow-up.
Main outcome	Diagnostic test accuracy (DTA)
Target condition	Active SARS-CoV-2 infection
Study design	Diagnostic cross-sectional or cohort studies with prospective sampling.
Unit of analysis	Individual study participants
Sample size	At least 10 (pediatric)[a] study participants each identified as positive or negative by the reference standard
Reported results	Sufficient data that allows constructing a complete 2x2 contingency table for (pediatric)[a] study participants per index test
Publication type	Full-text journal articles (including preprints) and reports (including clinical study reports)
Language	English or German

a: upon availability of pediatric study data

Table 2: Data extraction items

General study characteristics	• First author • Publication date • Publication status • Study design • Type of enrolment • Indication for testing • Inclusion and exclusion criteria • Definition of symptoms suggestive for infection with SARS-CoV-2 • Setting • Location • Country • Total number of study participants • Number of pediatric study participants • Recruitment period • Funding sources • Potential conflicts of interest • Study registry entry
Characteristics of pediatric study population	• Age • Proportion of males • Exposure history • Proportion of symptomatic individuals at the time of testing (if applicable) • Duration of symptoms prior to testing (if applicable)
Index test	• Name • Manufacturer • Regulatory status • Assay target • Test method • Readout • Target analyte • Specimen type used in study • Conduct of test according to manufacturer's instructions for use (as judged and reported by authors)
Reference standard	• Name • Manufacturer • Viral target(s) • (Pre-specified) positivity threshold(s) • Specimen type used in study
Flow and timing	• Specimen for index test collected by • Specimen for reference standard collected by • Time interval between specimen collection for index test and reference standard • Time interval between specimen collection and use of index test • Time interval between specimen collection and use of reference standard • Index test performed by • Result of index test interpreted by • Reference standard

	• Result of reference standard interpreted by • Blinding • Time to result index test • Time to result reference standard • Inconclusive or invalid result(s) of index test • Inconclusive or invalid result(s) of reference standard • Missing data
Reported outcomes for pediatric study population	• True positives (TP) • False negatives (FN) • True negatives (TN) • False positives (FP) (if available: separate outcome data depending on symptom status, symptom onset or positivity threshold of reference standard)

Table 3: Study pool of the systematic review

Study identifier	Data sources	Registry entry
Akingba	Preprint [48], unpublished data provided by author	N/A
Bianco	Journal article [50], unpublished data provided by author	N/A
Drevinek	Preprint [51], unpublished data provided by author	N/A
Gonzalez-Donapetry	Journal article [37]	N/A
Homza	Journal article [54], unpublished data provided by author	N/A
Kiyasu	Preprint [67], unpublished data provided by author	N/A
L'Huillier	Preprint [38]	N/A
Möckel	Journal article [39]	yes[a]
Pilarowski	Journal article [40]	N/A
Pollock a	Journal article [41]	N/A
Pollock b	Preprint [42]	N/A
Prince-Guerra	Journal article [43]	N/A
Sood	Journal article [44]	N/A
Shah	Journal article [61], supplementary file provided by authors (published as part of preprint [74] after finalization of the study pool)	N/A
Takeuchi	Journal article [63], unpublished data provided by author	N/A
Torres	Journal article [64], unpublished data provided by author	N/A
Villaverde	Journal article [45]	N/A

N/A: not available

a: Study registry identifier: DRKS00019207

Table 4: Potentially relevant studies identified through searching clinical study registries.

Study registry identifier	Country	Enrollment	Ages eligible for study	Name of index test	Recruitment status[a] (study completion date)
NCT04513990	USA	1,500	not specified (children included)	unspecified point-of-care test	Recruiting (estimated: Apr 2021)
NCT04557046	USA	400	any	LumiraDx SARS-CoV-2 Ag Test	Recruiting (estimated: Dec 2021)
NCT04583189	France	500	≤18 years	Biosynex Covid-19 Ag BSS Rapid test	Completed (Nov 2020)
NCT04720235	USA	304	14-75 years	Lucira COVID-19 All-In-One Test Kit	Completed (Mar 2021)
NCT04750629	USA	100	≥ 1 year	CoviDx™ Rapid Antigen Test	Not yet recruiting (estimated: Mar 2021)
NCT04808921	USA	151	any	Xiamen Wiz Biotech SARS-CoV-2 Antigen Rapid Test	Completed (Apr 2021)
NCT04859023	France	10,000	≥10 years	unspecified SARS-CoV-2 antigen test	Completed (Feb 2021)
NCT04878068	not reported	300	≥ 12 years	Therma COVID-19 Rapid Antigen Test	Not yet recruiting (estimated: June 2021)

a: Status as of May 24, 2021

Table 5: Characteristics of included studies. All studies aimed at identifying individuals currently infected with SARS-CoV-2. The reference standard was RT-PCR performed in the laboratory setting.

Study identifier	Publication status (year)	Study design	Setting	Purpose of testing	Location (recruitment period)	Name of index test	Total number of study participants	Pediatric study participants				Funding / potential COI
								n	male (%)	symptomatic (%)	age (y)	
Akingba[a] [48]	preprint (2021)	cross-sectional	Community testing site (mobile clinic)	D	South Africa (Nov 20)	Panbio COVID-19 Ag Rapid Test	667	41	39.0	100[b]	median: 13[c] IQR: 10-16[c] range: 3-17[c]	none / none
Bianco[a] [50]	published (2021)	cross-sectional	Hospital ED, Hospital unit	n.r.	Italy (Oct-Dec 20)	LumiraDx SARS-CoV-2 Ag Test	907[d]	165	n.r.	9.7	mean: 7.2 range: 0-18	none / none
Drevinek[a] [51]	preprint (2020)	cross-sectional	Hospital TC	D, A, S	Czech Republic (Oct 20)	1: Panbio COVID-19 Ag Rapid Test 2: Standard F Covid-19 FIA Ag	591	31	38.7[c]	32.3[c]	median: 15[c] IQR: 13.5-16[c] range: 11-17[c]	public / none
Gonzalez-Donapetry [37]	published (2021)	cross-sectional	Hospital ED	D	Spain (Sept-Oct 20)	Panbio COVID-19 Ag Rapid Test	440	440	59.1	100[b]	median: 3 IQR: 1-7 range:0-15	none / none
Homza[a] [54]	published (2021)	cross-sectional	Hospital TC	D, A	Czech Republic (not reported)	ECOTEST COVID-19 Antigen Rapid Test	494	24	58.3	45.8	mean: 13.17 SD: 2.79 range: 7-17	public / none
Kiyasu[a,g] [67]	preprint (2021)	cohort	Hospital TC	n.r.	Japan (Oct 20-Jan 21)	QuickNavi COVID19 Ag	1881	90	68.9	4.4	median: 12[c] IRQ: 6-15[c] range: 0-17[c]	private / yes
L'Huillier [38]	preprint (2021)	cross-sectional	Hospital TC	D, A, S	Switzerland (Nov 20-Mar 21)	Panbio COVID-19 Ag Rapid Test	885	885	50.1	64.8	median: 11.8 IQR: 9.0-14.3 range: 0-16	public / none
Möckel [39]	published (2021)	cross-sectional	Hospital ED	D	Germany (Oct-Nov 20)	Roche SARS-CoV-2 Rapid Antigen Test	483	196[h]	55	87.1	median: 3 IQR: 1-9	public / none
Pilarowski [40]	published (2020)	cross-sectional	Community testing site	S	USA (Nov-Dec 20)	BinaxNOW COVID-19 Ag Card	3320	209	n.r.	n.r. 30.9[e]	≤18 (47% < 13)	public, private / yes
Pollock a	published	cross-	Community	S	USA	BinaxNOW	2482	928	47.0[c]	10.7	≤18	public /

[41]	(2021)	sectional	testing site		(Oct-Dec 20)	COVID-19 Ag Card					(69%[c] ≤ 13)	none
Pollock b [42]	preprint (2021)	cross-sectional	Community testing site	S	USA (Jan 21)	CareStart COVID-19 Antigen test	1603	253	46.2[c]	12.6	≤18 (62%[c] ≤ 13)	public / none
Prince-Guerra [43]	published (2021)	cross-sectional	Community testing site	S	USA (Nov 20)	BinaxNOW COVID-19 Ag Card	3419	236	n.r.	n.r. 24.2[e]	range: 10-17	n.r. / none
Shah [a] [61,74]	published (2021)	cohort	Community testing site	S	USA (Nov-Dec 20)	BinaxNOW COVID-19 Ag Card	2024	217	n.r.	53.4[c]	range: 5-17	public / none
Sood [44]	published (2021)	cross-sectional	Community testing site	S, A	USA (Nov-Dec 20)	BinaxNOW COVID-19 Ag Card	1429	783	49.5	23.5	range: 5-17 65%: 5-12 35%: 13-17	public, private / yes
Takeuchi [a,g] [63]	published (2021)	cohort	Hospital TC	D, A	Japan (Oct-Dec 20)	QuickNavi COVID19 Ag	1208	164	61.6	54.9	median: 10[c] IQR: 5-14[c] range: 0-17 [c]	private / yes
Torres [a] [64]	published (2021)	cross-sectional	Hospital TC	A	Spain (Oct-Nov 20)	Panbio COVID-19 Ag Rapid Test	634	73	47.9	0[f]	median: 13 range: 9-17	none / none
Villaverde [45]	published (2021)	cohort	Hospital ED	D	Spain (Sept-Oct 20)	Panbio COVID-19 Ag Rapid Test	1620	1620	n.r.	100[a]	range: 0-16	public / none

Abbreviations:
A: testing of asymptomatic individuals at an increased risk of infection due to previous exposure to SARS-CoV-2; D: diagnostic testing of symptomatic individuals; S: screening of individuals irrespective of symptoms (e.g. mass testing, pretravel testing)
Hospital ED: Hospital emergency department; Hospital TC: Hospital test center
n.r.: not reported

Footnotes:
a: Study included due to unpublished pediatric study data obtained from author via author queries. b: Not explicitly stated, but as per inclusion criteria only symptomatic study participants. c: own calculation d: analysis population (total number of study participants not reported) e: Value reported for whole study population. f: Not explicitly stated, but as per inclusion criteria only asymptomatic study participants. g: The study reported by Kiyasu et al. [67] is specified as "extension study" of a previous study reported by Takeuchi et al. [63]. Both studies were included in this systematic review and considered as two separate studies, due to different but overlapping recruitment periods, substantial differences in the proportion of symptomatic pediatric study participants and differences in how discordant RT-PCR test results were re-evaluated. h: The overall pediatric study population as defined by the authors consisted of n=202 individuals and included n=6 adult chaperones.

Table 6: Characteristics of the studies' index test and reference standard.

Study identifier	Index test				Reference standard			
	Name (manufacturer)	Test method[a] / readout[a]	Target analyte[a]	Specimen type used in study	RT-PCR assay	Viral target	Positivity threshold	Specimen type used in study
Akingba	Panbio COVID-19 Ag Rapid Test (Abbott)	LFA / visual	N protein	NP	Seegene nCoV assay	3 targets (not specified)	at least 1 target ct-value < 38 inconclusive: 2 targets negative and 1 target positive with ct-value ≥38	same swab used for antigen test
Bianco	LumiraDx SARS-CoV-2 Ag Test (LumiraDx)	microfluidic FIA / automated	N protein	nasal	XpertXpress SARS-CoV-2 assay (Cepheid)[b]	n.r.	n.r.	NP
Drevinek	1: Panbio COVID-19 Ag Rapid Test (Abbott) 2: Standard F Covid-19 FIA Ag (SD Biosensor)	1: LFA / visual 2: FIA / automated	1: N protein 2: N protein	1: NP 2: NP	Allplex SARS-nCoV-2 (Seegene)	N, E and RdRP/S genes	at least one target with ct-value ≤ 40	NP+OP
Gonzalez-Donapetry	Panbio COVID-19 Ag Rapid Test (Abbott)	LFA / visual	N protein	NP	Vircell SARS-CoV-2 real-time PCR kit (Vircell)	N and E gene	both targets with ct-value ≤ 40	NP
Homza	ECOTEST COVID-19 Antigen Rapid Test (Assure Tech)	LFA / visual	n.r.	NP (nostril 1)	COVID-19 Multiplex RT-PCR Kit (Diana Biotechnologies)	S gene and gene coding the EndoRNAse	n.r.	NP (nostril 2)
Kiyasu	QuickNavi COVID19 Ag (Denka)	LFA / visual	N protein	NP	RT-PCR (National Institute of Infectious Diseases, Japan)[c]	n.r.	n.r.	NP
L'Huillier	Panbio COVID-19 Ag Rapid Test (Abbott)	LFA / visual	N protein	NP	1: Cobas SARS-CoV-2 assay (Roche) or 2: Nimbus RT-PCR assay	1: n.r. 2: n.r.	1: unclear 2: unclear	NP
Möckel	Roche SARS-CoV-2 Rapid Antigen Test (SD Biosensors)	LFA / visual	N protein	ONP	1: Cobas SARS-CoV-2 assay (Roche) or 2: SARS-CoV-2 E-gene assay (TibMolbiol)	1: n.r. 2: E gene	1: unclear 2: unclear	ONP
Pilarowski	BinaxNOW COVID-19 Ag Card (Abbott)	LFA / visual	N protein	AN (bilateral)	RenegadeXP[d] (RenegadeBio)	N gene	"none", ct cutoff value =30 or 35	AN (bilateral)
Pollock a	BinaxNOW COVID-19 Ag Card (Abbott)	LFA / visual	N protein	AN (bilateral)	CRSP SARS-CoV-2 Real-time RT-PCR Diagnostic Assay (MIT/Harvard)	N2 gene	ct cutoff value = 40 (in addition: 25,30, 35)	AN (bilateral)

Pollock b	CareStart COVID-19 Antigen test (Access Bio)	LFA / visual	N protein	AN (bilateral)	CRSP SARS-CoV-2 Real-time RT-PCR Diagnostic Assay (MIT/Harvard)	N2 gene	ct cutoff value = 40 (in addition: 25,30, 35)	AN (bilateral)
Prince-Guerra	BinaxNOW COVID-19 Ag Card (Abbott)	LFA / visual	N protein	AN (bilateral)	1: CDC 2019-nCoV Real-time RT-PCR Diagnostic Panel or 2: Fosun COVID-19 RT-PCR Detection Kit	1: n.r. 2: n.r.	1: n.r. 2: n.r.	NP (bilateral)
Shah	BinaxNOW	LFA / visual	N protein	AN (nostril 1)	TaqPath SARS-CoV-2 Combo Kit (Thermo Fisher Scientific)	S, N and Orf1Ab genes	ct-value ≤ 37 for at least two targets; inconclusive: 1 target positive	AN (nostril 2)
Sood	BinaxNOW COVID-19 Ag Card (Abbott)	LFA / visual	N protein	AN	Curative SARS-Cov-2 Assay (EUA for testing at KorvaLabs)	n.r.	ct-value ≤ 40	oral fluid[e]
Takeuchi	QuickNavi COVID19 Ag (Denka)	LFA / visual	N protein	NP	RT-PCR (National Institute of Infectious Diseases, Japan)[f]	n.r.	n.r.	NP
Torres	Panbio COVID-19 Ag Rapid Test (Abbott)	LFA / visual	N protein	NP (left nostril)	TaqPath SARS-CoV-2 Combo Kit (Thermo Fisher Scientific)	N gene	ct-value ≤ 35 (in addition: ≤ 30, ≤ 25, ≤ 20)	NP (right nostril)
Villaverde	Panbio COVID-19 Ag Rapid Test (Abbott)	LFA / visual	N protein	NP	RT-PCR (not further specified)	E and RdRp genes	n.r.	NP

Abbreviations
RT-PCR: reverse transcription-polymerase chain reaction
AN: anterior nasal (nares); NP: nasopharyngeal; ONP: oro-nasopharyngeal, OP: oropharyngeal
LFA: lateral flow immunochromatographic assay; FIA: fluorescent immunoassay

Footnotes:
a: Technical specification taken from FIND Test Directory / manufacturer's IFU if not reported in paper. b: XpertXpress SARS-CoV-2 assay has FDA EUA for both point-of-care and laboratory use [https://www.fda.gov/media/136316/download - accessed online: 20.06.2021]. The authors reported that RT-PCR was performed "at the Microbiology and Virology unit" of the "University Hospital Citt`a della Salute e della Scienza di Torino, Turin (Italy)" which is, according to the authors, the "largest tertiary care facility in Europe" [50], therefore we considered the reference standard as eligible. c: classified as "reference real-time RT-PCR" which was performed at the manufacturer's site. Further, RT-PCR was performed in an in-house microbiology laboratory. In case of discordant RT-PCR test results, a re-evaluation was performed "with a GeneXpert for SARS-CoV-2". The final decision was based on the result of the latter RT-PCR test. d: PCR-positive results were confirmed by the standard US Centers for Disease Control and Prevention methodology [40]. e: The FDA's Accelerated Emergency Use Authorization (EUA) Summary [https://www.fda.gov/media/137089/download - accessed online: 30.05.2021] states that the "collection of [...] oral fluid specimens is limited to symptomatic individuals within 14 days of COVID-19 symptom onset. [...] Negative results for SARS-CoV-2 RNA from oral fluid specimens should be confirmed by testing of another specimen type authorized for use with this test if clinically indicated." f: classified as "reference real-time RT-PCR" which was performed at the manufacturer's site. Further, RT-PCR was performed in an in-house microbiology laboratory. In case of discordant PCR test results, a re-evaluation was performed using a BioFire Respiratory Panel 2.1 on the BioFire FilmArray system.

Table 7: Conduct, flow and timing, and interpretation of index test and reference standard

Study identifier	Timing of specimen collection for index test and reference standard	Index test					Reference standard			Missing data	Invalid or inconclusive tests
		Specimen collected by	Time to conduct of test after specimen collection	Test performed by / interpreted by	Blinded to reference standard	IFU-conform conduct[a]	Specimen collected by	Time to conduct of test	Blinded to index test		
Akingba	only one swab for both tests (swab used for Ag-test was subsequently used for RT-PCR	n.r.	n.r. (result reported to participants onsite)	n.r. / n.r.	n.r., result determined prior to conduct of RT-PCR	n.r.	n.r.	n.r. (swab previously used for Ag-test)	n.r.	n.r., no participant flow diagram provided	19/677 PCR inconclusive, pediatric subgroup: 2/41 PCR inconclusive
Bianco	"in parallel"	n.r.	n.r.	trained staff / n.r.	n.r.	yes	trained staff	within a few hours	n.r.	n.r., no participant flow diagram provided	n.r.
Drevinek	n.r., but same participant encounter	n.r.	immediately	n.r. / n.r.	n.r.	yes	n.r.	n.r.	n.r.	none, no participant flow diagram provided	0
Gonzalez-Donapetry	paired sample collection	n.r.	n.r.	n.r. / n.r.	n.r.	yes	n.r.	n.r.	n.r.	none, no participant flow diagram provided	0
Homza	paired sample collection	HCW	immediately	n.r. / n.r.	n.r.	yes	HCW	n.r.	n.r.	none, no participant flow diagram provided	0
Kiyasu	"simultaneously"	n.r.	n.r.	n.r. / n.r.	n.r.	yes	n.r.	n.r.	n.r.	5/1939[b] no symptom data, no participant flow diagram provided	0
L'Huillier	n.r., but same participant encounter	HCW	immediately	n.r. / two members of the study team independently (consensus	n.r., result determined prior to RT-PCR	yes	HCW	n.r.	n.r.	58/883 refused Ag-test, 2/825 Ag-test result not reported	1/825 Ag-test result invalid

				required)							
Möckel	n.r., but same participant encounter	HCW	immediately	HCW / two HCW (consensus required)	n.r., result determined prior to RT-PCR	yes	HCW	n.r. (time to result (h): median: 8.2 range:3.8-39)	yes	none	0
Pilarowski	paired sample collection	certified lab assistants	n.r. (1 hour from onsite registration to return of positive test result)	n.r. / certified technician readers	n.r., result determined prior to RT-PCR	n.r. (only specimen collection according to IFU reported)	certified lab assistants	n.r.	n.r.	none, no participant flow diagram provided	0
Pollock a	paired sample collection	trained staff	within 1 hour	laboratorian / two laboratorians independently (1st read = official result)	n.r., result determined prior to RT-PCR	yes	trained staff	n.r.	n.r.	94/2482 samples tested at <53°F, 54/2482 missing data	26/2482 inconclusive RT-PCR
Pollock b	paired sample collection	trained staff	99.7% within 1 hour	laboratorian / two laboratorians independently (1st read = official result)	n.r., result determined prior to RT-PCR	yes	trained staff	n.r.	n.r.	48/1603 invalid or missing RT-PCR result, 57/1603 missing clinical data	invalid missing RT-PCR results, see missing data
Prince-Guerra	paired sample collection	HCW	immediately	n.r. / n.r.	n.r.	yes	HCW	within 24-48 hours	n.r.	n.r., no participant flow diagram provided	n.r.
Shah	same participant encounter	participants (self-collected, supervised)	n.r. (participants provided documentation of the initial test result about 30 minutes after initial sample collection)	trained staff / n.r.	n.r., result determined prior to RT-PCR	yes	participants (self-collected, supervised)	n.r. (Specimen with inconclusive results were retested)	n.r.	7/2127 missing RT-PCR result, no participant flow diagram provided	4/2127 indeterminate Ag test result, 6/2127 inconclusive RT-PCR result
Sood	n.r., but same	trained staff	n.r.	n.r. / two study staff	n.r.	yes	participants (self-	n.r.	n.r.	4/783 (pediatric subgroup) reason not	5/779 (pediatric

	participant encounter			(no consensus required)			collected, supervised)			reported, no participant flow diagram provided	subgroup) inconclusive result of index test
Takeuchi	"simultaneously"	n.r.	immediately	n.r. / examiner	n.r.	yes	n.r.	in-house RT-PCR: same day as sample collection, reference RT-PCR: up to 1 week	n.r.	22/1208 not the first participant encounter, 4/1208 missing symptom data, no participant flow diagram provided	0
Torres	paired sample collection	HCW	immediately	n.r. / n.r.	n.r.	n.r.	HCW	within 24 hours of specimen collection	n.r.	none, no participant flow diagram provided	0
Villaverde	"concurrently"	HCW	n.r.	n.r. / HCW	n.r.	yes	HCW	within 24 hours of specimen collection	n.r.	none, no participant flow diagram provided	0

Abbreviations:
IFU: instructions for use
RT-PCR: reverse transcription-polymerase chain reaction
n.r.: not reported
HCW: health care worker

Footnotes:
a: as judged and reported by the authors
b: unit of analysis = samples, but unit of analysis for pediatric subgroup = individual study participants

Table 8: QUADAS-2 risk of bias and applicability concerns summary – review authors' judgment about each domain for 18 test evaluations reported in 17 included studies.

Study identifier	Risk of bias				Applicability concerns		
	Patient selection	Index test	Reference standard	Flow and timing	Patient selection	Index test	Reference standard
Akingba	unclear	unclear	unclear	low	low	unclear	low
Bianco	unclear	unclear	unclear	unclear	low	unclear	low
Drevinek (IT1)	unclear	unclear	unclear	low	low	unclear	low
Drevinek (IT2)	unclear	low	unclear	low	low	unclear	low
Gonzalez-D.	unclear	unclear	unclear	low	high	unclear	low
Homza	low	unclear	unclear	low	low	unclear	low
Kiyasu	unclear	unclear	unclear	low	low	unclear	low
L'Huillier	low	low	unclear	high	low	low	low
Möckel	low	low	low	low	low	unclear	low
Pilarowski	unclear	unclear	unclear	low	low	unclear	low
Pollock a	unclear	unclear	unclear	high	low	unclear	low
Pollock b	unclear	unclear	unclear	high	low	low	low
Prince-G.	unclear	unclear	unclear	unclear	low	low	low
Shah	unclear	unclear	unclear	low	low	unclear	low
Sood	unclear	high	unclear	unclear	low	high	low
Takeuchi	unclear	unclear	unclear	low	low	unclear	low
Torres	low	unclear	unclear	low	low	unclear	low
Villaverde	high	unclear	unclear	low	high	unclear	low

IT1: Index test 1; IT 2: Index test 2

Table 9: Calculated RT-PCR positivity rate, sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) with 95% confidence interval (CI) for each included study based on the 2x2 contingency tables extracted for the entire pediatric study populations irrespective of symptom status.

Study identifier	TP	FP	TN	FN	RT-PCR positivity rate	Sensitivity (95% CI)	Specificity (95% CI)	PPV (95% CI)	NPV (95% CI)
Akingba	9	0	28	2	28.2	81.8 (52.3-94.9)	100 (87.9-100)	95.0 (65.6-99.5)	91.9 (77.2-97.5)
Bianco	12	8	141	4	9.7	75.0 (50.5-89.8)	94.6 (89.8-97.3)	60.0 (38.7-78.1)	97.2 (93.1-98.9)
Drevinek (IT1)	8	0	19	4	38.7	66.7 (39.1-86.2)	100 (83.2-100)	94.4 (62.9-99.4)	81.2 (61.8-92.1)
Drevinek (IT2)	8	0	19	4	38.7	66.7 (39.1-86.2)	100 (83.2-100)	94.4 (62.9-99.4)	81.2 (61.8-92.1)
Gonzales-Donapetry	14	0	422	4	4.1	77.8 (54.8-91.0)	100 (99.1-100)	96.7 (74.7-99.7)	98.9 (97.4-99.6)
Homza	8	1	11	4	50.0	66.7 (39.1-86.2)	91.7 (64.6-98.5)	88.9 (56.5-98.0)	73.3 (48.0-89.1)
Kiyasu	7	0	80	3	11.1	70.0 (39.7-89.2)	100 (95.4-100)	93.8 (59.8-99.3)	95.8 (89.2-98.5)
L'Huillier	78	1	702	41	14.5	65.5 (56.6-73.5)	99.9 (99.2-100)	98.7 (93.2-99.8)	94.5 (92.6-95.9)
Möckel	18	1	176	7	12.4	72.0 (52.4-85.7)	99.4 (96.9-99.9)	94.7 (75.4-99.1)	96.2 (92.3-98.1)
Pilarowski	30	0	174	5	16.7	85.7 (70.6-93.7)	100 (97.8-100)	98.4 (86.3-99.8)	96.9 (93.3-98.6)
Pollock a	94	7	786	41	14.5	69.6 (61.4-76.8)	99.1 (98.2-99.6)	93.1 (86.4-96.6)	95.0 (93.3-96.3)
Pollock b	26	7	200	20	18.2	56.5 (42.2-69.8)	96.6 (93.2-98.4)	78.8 (62.3-89.3)	90.9 (86.4-94.0)
Prince-Guerra	9	1	213	13	9.3	40.9 (23.3-61.3)	99.5 (97.4-99.9)	90.0 (59.6-98.2)	94.2 (90.4-96.6)
Shah	25	0	182	10	16.1	71.4 (54.9-83.7)	100 (97.9-100)	98.1 (84.0-99.8)	94.6 (90.4-97.0)
Sood	127	9	539	99	29.2	56.2 (49.7-62.5)	98.4 (96.9-99.1)	93.4 (87.9-96.5)	84.5 (81.5-87.1)
Takeuchi	9	0	153	2	6.7	81.8 (52.3-94.9)	100 (97.6-100)	95.0 (65.6-99.5)	98.4 (95.0-99.5)
Torres	5	0	58	10	20.5	33.3 (15.2-58.3)	100 (93.8-100)	91.7 (51.7-99.1)	84.8 (74.5-91.4)
Villaverde	35	3	1540	42	4.8	45.5 (34.8-56.5)	99.8 (99.4-99.9)	92.1 (79.2-97.3)	97.3 (96.4-98.0)

TP: true positive, FP: false positive, TN: true negative, FN: false negative
IT1: Index test 1; IT 2: Index test 2

Table 10: Calculated RT-PCR positivity rate, sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) with 95% confidence interval (CI) for each included study based on the 2x2 contingency tables extracted for *symptomatic* pediatric study populations.

Study identifier	TP	FP	TN	FN	RT-PCR positivity rate	Sensitivity (95% CI)	Specificity (95% CI)	PPV (95% CI)	NPV (95% CI)
Akingba	9	0	28	2	28.2	81.8 (52.3-94.9)	100 (87.9-100)	95.0 (65.6-99.5)	91.9 (77.2-97.5)
Bianco	5	0	9	2	43.8	71.4 (35.9-91.8)	100 (70.1-100)	91.7 (51.7-99.1)	79.2 (50.9-93.3)
Drevinek (IT1)	6	0	3	1	70.0	85.7 (48.7-97.4)	100 (43.9-100)	92.9 (56.1-99.2)	70.0 (29.9-92.7)
Drevinek (IT2)	6	0	3	1	70.0	85.7 (48.7-97.4)	100 (43.9-100)	92.9 (56.1-99.2)	70.0 (29.9-92.7)
Gonzales-Donapetry	14	0	422	4	4.1	77.8 (54.8-91.0)	100 (99.1-100)	96.7 (74.7-99.7)	98.9 (97.4-99.6)
L'Huillier	65	1	443	24	16.7	73.0 (63.0-81.2)	99.8 (98.7-100)	98.5 (91.9-99.7)	94.9 (92.5-96.5)
Möckel	18	1	176	7	12.4	72.0 (52.4-85.7)	99.4 (96.9-99.9)	94.7 (75.4-99.1)	96.2 (92.3-98.1)
Pilarowski	12	0	23	1	36.1	92.3 (66.7-98.6)	100 (85.7-100)	96.2 (71.7-99.6)	94.0 (77.7-98.6)
Pollock a	22	0	65	4	28.6	84.6 (66.5-93.8)	100 (94.4-100)	97.8 (82.2-99.8)	93.6 (85.3-97.3)
Pollock b	7	3	20	2	28.1	77.8 (45.3-93.7)	87 (67.9-95.5)	70.0 (39.7-89.2)	90.9 (72.2-97.5)
Shah	20	0	89	7	23.3	74.1 (55.3-86.8)	100 (95.9-100)	97.6 (80.8-99.8)	92.3 (85.2-96.1)
Sood	56	4	91	31	47.8	64.4 (53.9-73.6)	95.8 (89.7-98.4)	93.3 (84.1-97.4)	74.6 (66.2-81.5)
Takeuchi	1	0	89	0	1.1	100 (20.7-100)	100 (95.9-100)	75.0 (19.8-97.3)	99.4 (94.9-99.9)
Villaverde	35	3	1540	42	4.8	45.5 (34.8-56.5)	99.8 (99.4-99.9)	92.1 (79.2-97.3)	97.3 (96.4-98.0)

TP: true positive, FP: false positive, TN: true negative, FN: false negative
IT1: Index test 1; IT 2: Index test 2

Table 11: Calculated RT-PCR positivity rate, sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) with 95% confidence interval (CI) for each included study based on the 2x2 contingency tables extracted for *asymptomatic* pediatric study populations.

Study identifier	TP	FP	TN	FN	RT-PCR positivity rate	Sensitivity (95% CI)	Specificity (95% CI)	PPV (95% CI)	NPV (95% CI)
Bianco	7	8	132	2	6.0	77.8 (45.3-93.7)	94.3 (89.1-97.1)	46.7 (24.8-69.9)	98.5 (94.7-99.6)
Drevinek (IT1)	2	0	16	3	23.8	40.0 (11.8-76.9)	100 (80.6-100)	83.3 (31.0-98.2)	82.5 (61.1-93.4)
Drevinek (IT2)	2	0	16	3	23.8	40.0 (11.8-76.9)	100 (80.6-100)	83.3 (31.0-98.2)	82.5 (61.1-93.4)
Kiyasu	7	0	76	3	11.6	70.0 (39.7-89.2)	100 (95.2-100)	93.8 (59.8-99.3)	95.6 (88.7-98.4)
L'Huillier	13	0	259	17	10.4	43.3 (27.4-60.8)	100 (98.5-100)	96.4 (73.2-99.6)	93.7 (90.2-96.0)
Pollock a	70	7	715	37	12.9	65.4 (56.0-73.8)	99.0 (98.0-99.5)	90.9 (82.4-95.5)	95.1 (93.3-96.4)
Pollock b	19	4	180	18	16.7	51.4 (35.9-66.6)	97.8 (94.5-99.2)	82.6 (62.9-93.0)	90.9 (86.1-94.2)
Shah	4	0	90	3	7.2	57.1 (25.0-84.2)	100 (95.9-100)	90.0 (46.3-99.0)	96.3 (90.3-98.6)
Sood	71	5	448	68	23.5	51.1 (42.9-59.2)	98.9 (97.4-99.5)	93.4 (85.5-97.2)	86.8 (83.6-89.5)
Takeuchi	8	0	64	2	13.5	80.0 (49.0-94.3)	100 (94.3-100)	94.4 (62.9-99.4)	96.3 (88.7-98.8)
Torres	5	0	58	10	20.5	33.3 (15.2-58.3)	100 (93.8-100)	91.7 (51.7-99.1)	84.8 (74.5-91.4)

TP: true positive, FP: false positive, TN: true negative, FN: false negative
IT1: Index test 1; IT 2: Index test 2

Table 12: Calculated RT-PCR positivity rate, sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) with 95% confidence interval (CI) for each included study based on the 2x2 contingency tables extracted for *mixed* pediatric study populations.

Study identifier	TP	FP	TN	FN	RT-PCR positivity rate	Sensitivity (95% CI)	Specificity (95% CI)	PPV (95% CI)	NPV (95% CI)
Homza	8	1	11	4	50.0	66.7 (39.1-86.2)	91.7 (64.6-98.5)	88.9 (56.5-98.0)	73.3 (48.0-89.1)
Pilarowski	18	0	137	4	13.8	81.8 (61.5-92.7)	100 (97.3-100)	97.4 (79.1-99.7)	96.8 (92.5-98.7)
Prince-Guerra	9	1	213	13	9.3	40.9 (23.3-61.3)	99.5 (97.4-99.9)	90.0 (59.6-98.2)	94.2 (90.4-96.6)

TP: true positive, FP: false positive, TN: true negative, FN: false negative

Table 13: Calculated RT-PCR positivity rate, sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) with 95% confidence interval (CI) for each included study based on the 2x2 contingency tables extracted for entire pediatric study populations irrespective of symptom status when the RT-PCR cycle threshold cutoff value is set to 30.

Study identifier	TP	FP	TN	FN	RT-PCR positivity rate	Sensitivity (95% CI)	Specificity (95% CI)	PPV (95% CI)	NPV (95% CI)
Akingba	9	0	30	0	23.1	100 (70.1-100)	100 (88.6-100)	95.0 (65.6-99.5)	98.4 (86.3-99.8)
Pilarowski	24	6	179	0	11.5	100 (86.2-100)	96.8 (93.1-98.5)	79.0 (61.9-89.7)	99.7 (97.4-100)
Pollock a	84	17	818	9	10.0	90.3 (82.6-94.8)	98.0 (96.8-98.7)	83.2 (74.7-89.2)	98.9 (97.9-99.4)
Pollock b	24	9	215	5	11.5	82.8 (65.5-92.4)	96.0 (92.5-97.9)	72.7 (55.8-84.9)	97.7 (94.8-99.0)
Sood	42	91	625	11	6.9	79.2 (66.5-88.0)	87.3 (84.7-89.5)	31.6 (24.3-39.9)	98.3 (96.9-99.0)
Torres	5	0	60	8	17.8	38.5 (17.7-64.5)	100 (94.0-100)	91.7 (51.7-99.1)	87.7 (77.9-93.5)

TP: true positive, FP: false positive, TN: true negative, FN: false negative

Table 14: Calculated RT-PCR positivity rate, sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) with 95% confidence interval (CI) for each included study based on the 2x2 contingency tables extracted for entire pediatric study populations irrespective of symptom status when the RT-PCR cycle threshold cutoff value is set to 25.

Study identifier	TP	FP	TN	FN	RT-PCR positivity rate	Sensitivity (95% CI)	Specificity (95% CI)	PPV (95% CI)	NPV (95% CI)
Akingba	4	5	30	0	10.3	100 (51.0-100)	85.7 (70.6-93.7)	45.0 (20.1-72.6)	98.4 (86.3-99.8)
Pollock a	61	40	826	1	6.7	98.4 (91.4-99.7)	95.4 (93.8-96.6)	60.4 (50.6-69.4)	99.9 (99.3-100)
Pollock b	20	13	220	0	7.9	100 (83.9-100)	94.4 (90.7-96.7)	60.3 (43.6-74.9)	99.8 (97.9-100)
Sood	15	118	635	1	2.1	93.8 (71.7-98.9)	84.3 (81.6-86.8)	11.3 (7.0-17.8)	99.8 (99.1-100)
Torres	4	1	65	3	9.6	57.1 (25.0-84.2)	98.5 (91.9-99.7)	80.0 (37.5-96.4)	95.6 (87.8-98.5)

TP: true positive, FP: false positive, TN: true negative, FN: false negative

Table 15: Results of the bivariate meta-analyses: pooled sensitivity and specificity with 95% confidence interval (CI).

	Sensitivity (95% CI)	Specificity (95% CI)
All studies	64.2 (57.4-70.5)	99.1 (98.2-99.5)
Symptom status: symptomatic	71.8 (63.6-78.8)	98.7 (96.6-99.5)
Symptom status: asymptomatic	56.2 (47.6-64.4)	98.6 (97.3-99.3)
Symptom status: mixed	63.4 (37.3-83.5)	98.7 (90.8-99.8)
Setting: community testing site	64.1 (54.7-72.6)	98.7 (97.6-99.3)
Setting: hospital test center / emergency department	64.1 (53.8-73.2)	99.4 (98.2-99.8)
Sample type (index test): nasopharyngeal	64.3 (54.7-73.0)	99.4 (98.5-99.8)
Sample type (index test): not nasopharyngeal	64.6 (54.4-73.7)	98.5 (96.7-99.3)
Sample type (reference standard): nasopharyngeal	65.4 (56.3-73.5)	99.1 (97.7-99.7)
Sample type (reference standard): not nasopharyngeal	64.2 (53.1-74.0)	98.9 (97.6-99.5)
RT-PCR Ct cutoff value = 25	92.4 (72.7-98.2)	92.7 (85.4-96.5)
RT-PCR Ct cutoff value = 30	83.3 (63.9-93.4)	96.1 (91.8-98.2)
Publication status: preprint	63.2 (55.6-70.3)	98.9 (95.9-99.7)
Publication status: peer-reviewed	64.3 (54.8-72.7)	99.1 (98.1-99.6)
Test type (most used): Panbio	60.8 (46.9-73.1)	99.7 (99.2-99.9)
Test type (most used): BinaxNOW	66.3 (53.0-77.5)	99.1 (98.2-99.5)